Identification of Specific Molecular Signatures in Pediatric, Adolescent, and Young Adult Rhabdomyosarcoma Through Spatial Proteome Analysis Using Mass Spectrometry

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-25
SponsorLille University

About this trial

This non-interventional study aims to develop spatial proteomics for analyzing small FFPE tumor samples in rhabdomyosarcoma. It will identify molecular signatures linked to tumor regions, subtypes, survival, and treatment resistance, using pre-existing samples and data.

Eligibility criteria

Qualifiers

Age between 0 and 25 years at the time of initial diagnosis

Diagnosis of rhabdomyosarcoma confirmed histologically

Care at the Oscar Lambret Center between January 2005 and November 2024

No objection to the re-use of data and biological samples collected as part of care for research activities.

Disqualifiers

Unavailability of biological sample in FFPE from biopsy and/or surgical specimen for diagnosis at Centre Oscar Lambret;

Patient under guardianship or trusteeship.

Trial design

Treatments tested in this trial

  • None AHT

Treatment groups

No treatment groups listed

Sponsors and collaborators

Lille University

Lead sponsor

Centre Oscar Lambret, Lille, France

Collaborator